AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20418006 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback (FB)
Number of subjects: 64
Study 20418006 — intervention group
Group type: COMPARATOR
Intervention: No feedback (NFB)
Number of subjects: 64
Study 18398944 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFeron‐TB Gold In‐Tube assay (QFT)
Number of subjects: 101
Study 18398944 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin skin test (TST)
Number of subjects: 101
Study 15472009 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar vibration at 45 Hz
Number of subjects: 18
Study 15472009 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar vibration
Number of subjects: 18
Study 12100113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg
Number of subjects: 80
Study 12100113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 80
Study 12100113 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg
Number of subjects: 80
Study 12100113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9759992 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 103
Study 9759992 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 103
Study 8172870 — intervention group
Group type: EXPERIMENTAL
Intervention: 57Fe
Number of subjects: 9
Study 8172870 — intervention group
Group type: EXPERIMENTAL
Intervention: 58Fe
Number of subjects: 9
Study 3127483 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2%
Number of subjects: 30
Study 3127483 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine 0.1%
Number of subjects: 30
Study 30442284 — intervention group
Group type: EXPERIMENTAL
Intervention: TF‐TAVR
Number of subjects: 1204
Study 30442284 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 1204
Study 27223846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg once-daily
Number of subjects: 0
Study 27223846 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once-daily
Number of subjects: 0
Study 25573349 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex PCR (mPCR) performed as an addition to standard diagnostics
Number of subjects: 150
Study 25573349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no awareness of PCR result)
Number of subjects: 150
Study 25573349 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (mPCR)
Number of subjects: 150
Study 25573349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mPCR)
Number of subjects: 150
Study 23149259 — intervention group
Group type: EXPERIMENTAL
Intervention: Keeping animals in the same group
Number of subjects: 77
Study 23149259 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventing direct contact with neighbouring cattle
Number of subjects: 77
Study 23149259 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining dry bedding
Number of subjects: 77
Study 23149259 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining a closed herd using quarantine procedures
Number of subjects: 77
Study 20506355 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 163
Study 20506355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 18226725 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (M)
Number of subjects: 34
Study 18226725 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide-oxygen mixture (E)
Number of subjects: 34
Study 18226725 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine + Nitrous oxide-oxygen mixture (ME)
Number of subjects: 34
Study 16995547 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 80
Study 14570640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 100
Study 14570640 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 100
Study 11048472 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg sustained-release diltiazem
Number of subjects: 50
Study 11048472 — intervention group
Group type: COMPARATOR
Intervention: 5 mg ramipril
Number of subjects: 50
Study 8905026 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (50, 60 mg/m2) followed by paclitaxel (155, 175 mg/m2) every 3 weeks
Number of subjects: 30
Study 8418709 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU/kg rHuEPO subcutaneously once a week
Number of subjects: 24
Study 8418709 — intervention group
Group type: COMPARATOR
Intervention: Iron only (Control)
Number of subjects: 24
Study 3533292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cefazolin (Fowler's protocol)
Number of subjects: 45
Study 3533292 — intervention group
Group type: COMPARATOR
Intervention: Control group with i.v. gentamycin or tobramycin and clindamycin or metronidazole
Number of subjects: 45
Study 3533292 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 45
Study 29324186 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT) ingestion (600 mg·kg‐1) during recovery
Number of subjects: 20
Study 29324186 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC) during recovery
Number of subjects: 20
Study 24362634 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + PRF
Number of subjects: 22
Study 24362634 — intervention group
Group type: COMPARATOR
Intervention: CAF + SCTG
Number of subjects: 22
Study 22574589 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishen Jiangzhuo Granule (YJG)
Number of subjects: 53
Study 22574589 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 20374985 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Support Technicians (PSTs) implementation
Number of subjects: 0
Study 19120293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Number of subjects: 0
Study 19120293 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral insulin
Number of subjects: 0
Study 19120293 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin
Number of subjects: 0
Study 19120293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal insulin
Number of subjects: 0
Study 19120293 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of cow's milk from infant feeding
Number of subjects: 0
Study 15877709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 15877709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12665761 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS (Endoscopic Ultrasound)
Number of subjects: 485
Study 12665761 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-based strategy
Number of subjects: 485
Study 12665761 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 485
Study 10323426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Pringle maneuver (20 minutes with 5-minute clamp-free interval)
Number of subjects: 112
Study 10323426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Pringle maneuver
Number of subjects: 112
Study 10323426 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated ischemic time longer than 120 minutes
Number of subjects: 112
Study 10323426 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Pringle maneuver)
Number of subjects: 112
Study 8607507 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium (660 mg/d)
Number of subjects: 30
Study 8607507 — intervention group
Group type: EXPERIMENTAL
Intervention: acetaminophen (4000 mg/d)
Number of subjects: 30
Study 8607507 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 8607507 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium (660 mg/d) in subjects with endoscopic changes
Number of subjects: 30
Study 8607507 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium (660 mg/d) in subjects without endoscopic damage
Number of subjects: 30
Study 8607507 — intervention group
Group type: EXPERIMENTAL
Intervention: initial mucin in subjects with endoscopic changes after naproxen
Number of subjects: 30
Study 8607507 — intervention group
Group type: EXPERIMENTAL
Intervention: initial hydrophobicity in subjects with endoscopic changes after naproxen
Number of subjects: 30
Study 8607507 — intervention group
Group type: EXPERIMENTAL
Intervention: initial pepsin in subjects with endoscopic changes after naproxen
Number of subjects: 30
Study 2015153 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms
Number of subjects: 46
Study 2015153 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam 1 mg
Number of subjects: 46
Study 2015153 — intervention group
Group type: COMPARATOR
Intervention: Both drugs (Clonidine 150 micrograms and Flunitrazepam 1 mg)
Number of subjects: 46
Study 6116723 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonococcal pilus vaccine
Number of subjects: 71
Study 6116723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 31151424 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole image registration
Number of subjects: 60
Study 31151424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral registration
Number of subjects: 60
Study 31151424 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue tumor registration
Number of subjects: 60
Study 31151424 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral body registration
Number of subjects: 60
Study 28787252 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonally involving training program based on self‐determination theory principles
Number of subjects: 382
Study 28787252 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 382
Study 27058970 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Collaborative intervention (Phase 1, months 1-9)
Number of subjects: 38
Study 27058970 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (Phase 1, months 1-9)
Number of subjects: 38
Study 22902185 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose B vitamins
Number of subjects: 2056
Study 22902185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2056
Study 21975348 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-38431055 (2.5-800 mg)
Number of subjects: 0
Study 21975348 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-38431055 (in graded glucose infusion study)
Number of subjects: 0
Study 21975348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18268112 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO)
Number of subjects: 81
Study 18268112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 16998362 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 12
Study 12710749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-abrasive air polishing powder
Number of subjects: 23
Study 12710749 — intervention group
Group type: COMPARATOR
Intervention: Curets (positive control)
Number of subjects: 23
Study 12710749 — intervention group
Group type: COMPARATOR
Intervention: Subgingival plaque sampling alone (negative control)
Number of subjects: 23
Study 10898693 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole and clarithromycin
Number of subjects: 10
Study 10898693 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole and clarithromycin together
Number of subjects: 10
Study 8985111 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 50 units of botulinum toxin type A (BTX‐A) into the mid belly of the gastrocnemius muscle (distally at three sites)
Number of subjects: 17
Study 8985111 — intervention group
Group type: COMPARATOR
Intervention: Injection of 50 units of botulinum toxin type A (BTX‐A) into the proximal site near the muscular origin of the gastrocnemius muscle
Number of subjects: 17
Study 1727998 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (0.15 mg/kg per dose)
Number of subjects: 28
Study 1727998 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 28
Study 6319452 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (0.5, 1.0, and 1.5 mg/kg)
Number of subjects: 0
Study 6319452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine (serotonin antagonist) pretreatment before fenfluramine administration
Number of subjects: 0
Study 6319452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29032481 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitioning Together program (8-week multi-family group psychoeducation)
Number of subjects: 41
Study 29032481 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitioning Together program
Number of subjects: 41
Study 29032481 — intervention group
Group type: COMPARATOR
Intervention: Control condition (waitlist)
Number of subjects: 41
Study 28846787 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 65
Study 28846787 — intervention group
Group type: COMPARATOR
Intervention: Conventional osteotome
Number of subjects: 65
Study 26652168 — intervention group
Group type: EXPERIMENTAL
Intervention: Continence promotion intervention
Number of subjects: 1000
Study 23100457 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 10
Study 23100457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21247573 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine (CHX) vaginal washing
Number of subjects: 502
Study 21247573 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 502
Study 18336635 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 211
Study 18336635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 16861420 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided remifentanil/propofol regimen
Number of subjects: 54
Study 16861420 — intervention group
Group type: COMPARATOR
Intervention: Clinically guided regimen (SAS group)
Number of subjects: 54
Study 16861420 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided regimen
Number of subjects: 54
Study 12874612 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical home blood pressure (HBP) measurement (5 days, four times daily)
Number of subjects: 411
Study 12874612 — intervention group
Group type: COMPARATOR
Intervention: Clinic blood pressure (CBP) measurement
Number of subjects: 411
Study 11155608 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized professional support
Number of subjects: 51
Study 11155608 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing care
Number of subjects: 51
Study 9177389 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 IU/m2/day GH
Number of subjects: 36
Study 9177389 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 IU/m2/day GH
Number of subjects: 36
Study 9177389 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 IU/m2/day GH
Number of subjects: 36
Study 9177389 — intervention group
Group type: COMPARATOR
Intervention: GH (2 IU/m2/day) after 6 months of placebo
Number of subjects: 36
Study 9177389 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 36
Study 1560163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (400 mg tablet)
Number of subjects: 8
Study 1560163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3157706 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 62
Study 3157706 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 62
Study 29754655 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMI
Number of subjects: 83
Study 29754655 — intervention group
Group type: EXPERIMENTAL
Intervention: UA/NSTEMI
Number of subjects: 83
Study 26914263 — intervention group
Group type: EXPERIMENTAL
Intervention: Motives Feedback Condition (MFC)
Number of subjects: 170
Study 26914263 — intervention group
Group type: COMPARATOR
Intervention: Standard Feedback Condition (SFC)
Number of subjects: 170
Study 24777019 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronal muscle splitting technique
Number of subjects: 24
Study 24777019 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coronal muscle splitting)
Number of subjects: 24
Study 22560357 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered tailored education and coaching (TEC)
Number of subjects: 258
Study 22560357 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 258
Study 22560357 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic change (following TEC)
Number of subjects: 258
Study 20923577 — intervention group
Group type: EXPERIMENTAL
Intervention: HSD/5D
Number of subjects: 61
Study 20923577 — intervention group
Group type: COMPARATOR
Intervention: Ringer's Lactate (RL)
Number of subjects: 61
Study 18354285 — intervention group
Group type: EXPERIMENTAL
Intervention: FS 4IU VH S/D (fibrin sealant containing 4 IU/ml thrombin)
Number of subjects: 138
Study 18354285 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 138
Study 17022376 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment for 6 weeks
Number of subjects: 192
Study 17022376 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment for 12 weeks
Number of subjects: 192
Study 12749497 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 2178
Study 10952474 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg once daily in the morning
Number of subjects: 24
Study 10952474 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg once daily in the evening
Number of subjects: 24
Study 10952474 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg twice daily
Number of subjects: 24
Study 10952474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8636663 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructed group (given instruction on interchangeability)
Number of subjects: 0
Study 8636663 — intervention group
Group type: EXPERIMENTAL
Intervention: Queried group (asked about basis for test-trial responding)
Number of subjects: 0
Study 8636663 — intervention group
Group type: COMPARATOR
Intervention: Standard group (neither instructed nor queried)
Number of subjects: 0
Study 8636663 — intervention group
Group type: COMPARATOR
Intervention: Baseline trials
Number of subjects: 0
Study 8636663 — intervention group
Group type: COMPARATOR
Intervention: Symmetry trials
Number of subjects: 0
Study 8636663 — intervention group
Group type: COMPARATOR
Intervention: Transitivity trials
Number of subjects: 0
Study 8636663 — intervention group
Group type: COMPARATOR
Intervention: Combined transitivity and symmetry trials
Number of subjects: 0
Study 8636663 — intervention group
Group type: COMPARATOR
Intervention: Nodal distance (one through five nodes)
Number of subjects: 0
Study 1627427 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation therapy
Number of subjects: 1153
Study 1627427 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 1153
Study 6508324 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin (B) with maintenance chemotherapy
Number of subjects: 101
Study 6508324 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy alone (C)
Number of subjects: 101
Study 6508324 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin (B) in patients over 50 years of age
Number of subjects: 101
Study 6508324 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy alone (C) in patients over 50 years of age
Number of subjects: 101
Study 31013182 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLN) 10 mg orally on days 1 to 4
Number of subjects: 64
Study 31013182 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (HAL) 1 mg orally on day 1 and 0.5 mg twice daily on days 2 to 4
Number of subjects: 64
Study 29494473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based audiometric applications
Number of subjects: 107
Study 29494473 — intervention group
Group type: COMPARATOR
Intervention: Conventional audiometry
Number of subjects: 107
Study 26537976 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative depression (BDI score >3)
Number of subjects: 359
Study 26537976 — intervention group
Group type: COMPARATOR
Intervention: No preoperative depression (BDI score ≤3)
Number of subjects: 359
Study 25409545 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF)
Number of subjects: 504
Study 25409545 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration
Number of subjects: 504
Study 25409545 — intervention group
Group type: COMPARATOR
Intervention: Exclusively flossing (control group)
Number of subjects: 504
Study 25409545 — intervention group
Group type: EXPERIMENTAL
Intervention: SDF, Resin infiltration, Exclusively flossing
Number of subjects: 504
Study 23019940 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Zhebei Granule (CZG)
Number of subjects: 41
Study 23019940 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard chemotherapy)
Number of subjects: 41
Study 20596692 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU vitamin D(3)
Number of subjects: 61
Study 20596692 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU vitamin D(3)
Number of subjects: 61
Study 20596692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 18047643 — intervention group
Group type: EXPERIMENTAL
Intervention: DECISION+ program in shared decision making (experimental group)
Number of subjects: 5
Study 18047643 — intervention group
Group type: COMPARATOR
Intervention: Delayed DECISION+ group (control group)
Number of subjects: 5
Study 15661822 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of training
Number of subjects: 22
Study 15661822 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of training
Number of subjects: 22
Study 15661822 — intervention group
Group type: COMPARATOR
Intervention: Baseline (compared to controls)
Number of subjects: 22